Alkem Labs Q1FY27 Revenue Up 10.9% to ₹37,402 Crore
Alkem Laboratories reported Q1FY27 revenue of ₹37,402 crore, up 10.9% YoY. India sales grew 10.3% to ₹24,978 crore, while international sales increased 16.0% to ₹12,223 crore. EBITDA rose 3.7% to ₹7,661 crore. Net profit declined 21.7% to ₹5,200 crore.
The revenue growth and market outperformance are positive indicators. However, the decline in net profit and the MD's commentary on areas needing improvement suggest a mixed impact, warranting a medium assessment.
The company reported strong revenue and EBITDA growth, along with outperformance in the domestic market and significant growth in non-US international markets. While net profit saw a decline, the overall revenue and operational performance indicate a positive trend.
Alkem Laboratories Ltd. announced its financial results for the first quarter ended June 30, 2026 (Q1FY27), reporting a total revenue from operations of ₹37,402 million, a year-on-year growth of 10.9%.
The company's India sales reached ₹24,978 million, showing a 10.3% YoY growth. In the international markets, sales were ₹12,223 million, marking a significant 16.0% YoY growth. EBITDA stood at ₹7,661 million, with an EBITDA margin of 20.5%, reflecting a 3.7% YoY increase. R&D expenses for the quarter were ₹1,502 million, representing 4.0% of total revenue from operations. Profit before tax (before exceptional item) grew by 1.8% YoY to ₹7,720 million. However, Net Profit (after Non-Controlling interest) saw a YoY de-growth of 21.7%, settling at ₹5,200 million.
In the domestic business, Alkem reported a 13.2% YoY growth compared to the Indian Pharmaceutical Market (IPM) growth of 12.2%, outperforming the market by 100 basis points. The company outperformed IPM in seven key focused therapies. The US business recorded sales of ₹7,439 million, a 6.5% YoY growth, contributing 20.0% to total sales. Non-US international sales showed robust growth of 34.5% YoY, reaching ₹4,785 million and contributing 12.9% to total sales.
Mr. Sandeep Singh, MD of Alkem, commented on the results, stating, “We have started FY27 on a steady note, with healthy growth across our India and international businesses. Our India business continued to outperform the market, while the strong growth in our non-US international markets was encouraging. At the same time, there are areas where we need to improve, particularly in strengthening execution, addressing operational and regulatory priorities, and improving the consistency of performance across our businesses. We are also investing in R&D, MedTech and Biotech as we build our next phase of growth.” The company also announced its Q1FY27 conference call scheduled for August 14, 2026, at 4:30 PM IST.
What to do with a filing like this
Alkem Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alkem Laboratories Limited. Read the original for the full detail.